Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces Enterprise 3D Modeling Deal With AI Revenue Driving Growth (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioRestorative Therapies Inc BRTX

Healthcare Biotechnology
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells... see more

Recent & Breaking News (NDAQ:BRTX)

BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

GlobeNewswire 2 days ago

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

GlobeNewswire 3 days ago

BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 14, 2025

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

GlobeNewswire May 13, 2025

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

GlobeNewswire May 8, 2025

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

GlobeNewswire May 7, 2025

Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies

TheNewsWire April 23, 2025

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

TheNewsWire April 16, 2025

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

GlobeNewswire April 15, 2025

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

GlobeNewswire April 10, 2025

BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

GlobeNewswire March 27, 2025

BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025

GlobeNewswire March 20, 2025

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

GlobeNewswire February 27, 2025

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

GlobeNewswire February 26, 2025

BioRestorative to Provide a Positive FDA Update on Clinical Pipeline

GlobeNewswire February 25, 2025

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

GlobeNewswire February 20, 2025

BRTX-100 Front and Center at ORS 2025

GlobeNewswire February 10, 2025

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

GlobeNewswire December 5, 2024

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

GlobeNewswire November 13, 2024

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024